Dual-Adjuvant Mucosal Vaccine Leveraging Mast Cell and TLR9 Agonists for Protection Against Poxvirus Infection

Q: What does this research mean for the field?

A dual-adjuvant mucosal vaccine combining mast cell and TLR9 agonists provides protection against poxvirus infection. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Connor Murphy; Grace Williamson; Luis Ontiveros-Padilla; Aaron T. Hendricksen; Brandi T. Johnson‐Weaver; Hae Woong Choi; David Gooden; Santhosh Kalpathy; Alexandra M Lopez; Erik S. Pena; Jacob M. Bachelder; Rani S. Sellers; Soman Abraham; Herman Staats; Kristy Ainslie

doi:10.1039/d5pm00380f

January 1, 2026RSC PharmaceuticsOpen Access

Dual-Adjuvant Mucosal Vaccine Leveraging Mast Cell and TLR9 Agonists for Protection Against Poxvirus Infection

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of a dual-adjuvant mucosal vaccine utilizing mast cell and TLR9 agonists in providing protection against poxvirus infection.
Utilized mast cell and TLR9 agonists as adjuvants in vaccine formulation
Evaluated protection metrics against poxvirus infection
The dual-adjuvant vaccine resulted in a significant increase in protective immunity compared to control groups
Mast cell activation and TLR9 agonist administration enhanced antibody responses against poxvirus
Higher survival rates observed in vaccinated groups, indicating effective immune priming

Implication

Investigates dual-adjuvant vaccine efficacy against poxvirus infection, highlighting immune system enhancement.

Abstract

Mast cells (MC) are innate immune cells that are predominantly localized under the skin and at mucosal surfaces, and play a role in numerous physiological processes, including host responses to...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Murphy et al. (2026) studied this question.

synapsesocial.com/papers/6a23baa771a5da9775e7660c https://doi.org/10.1039/d5pm00380f

View Full Paper

Ask AI

Bookmark

Share

Dual-Adjuvant Mucosal Vaccine Leveraging Mast Cell and TLR9 Agonists for Protection Against Poxvirus Infection

Key Points

Implication

Abstract

Discussion

Cite This Study

Dual-Adjuvant Mucosal Vaccine Leveraging Mast Cell and TLR9 Agonists for Protection Against Poxvirus Infection

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from RSC Pharmaceutics

Keep reading

More related papers

More from RSC Pharmaceutics